Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.44%
#3 Glidr Glidr +35.94%
#4 Humanity Humanity +25.03%
#5 Tutorial Tutorial +21.66%
#6 Enso Enso +21.56%
#7 Codatta Codatta +19.97%
#8 Walrus Walrus +19.47%
#9 BOOK OF MEME BOOK OF MEME +18.59%
#10 Ribbita by Virtuals Ribbita by Virtuals +13.44%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASI
Classifica tra le azioni #36784
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the... CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.
Prezzo delle azioni
$0.15
Ultima sincronizzazione: 2026-04-13
Capitalizzazione di mercato
$2.33M
Variazione (1 giorno)
3.88%
Variazione (1 anno)
-93.70%
Paese
CN
Scambia CASI Pharmaceuticals, Inc. (CASI)

Categoria

Healthcare
Storico dividendi per CASI Pharmaceuticals, Inc. (CASI)
CASI Pharmaceuticals, Inc. (simbolo azionario: CASI) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per CASI Pharmaceuticals, Inc. (CASI) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
29.00%
BE